Skip to main content Accessibility help
×
Home

Editorial Review: Therapeutic Trials in Multiple Sclerosis

  • J.H. Noseworthy (a1), T.P. Seland (a1) and G.C. Ebers (a1)
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Editorial Review: Therapeutic Trials in Multiple Sclerosis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Editorial Review: Therapeutic Trials in Multiple Sclerosis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Editorial Review: Therapeutic Trials in Multiple Sclerosis
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

Corresponding author

Department of Clinical Neurological Sciences, University Hospital, 339 Windermere Road, London, Ontario, Canada N6A 5A5

References

Hide All
Abreu, SL (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immuno Commun. 11: 17.
Aimard, G, Confavreux, C, Trouillas, P, et al. (1977) Our experience of azathioprine treatment in multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in Multiple Sclerosis, Ghent, Belgium, European Press, pp. 3845.
Alvord, EG, Shaw, C, Hruby, S (1979) Myelin basic protein treatment of experimental allergic encephalomyelitis in monkeys. Ann. Neurol. 6: 469473.
Basten, A, Pollard, JD, Stewart, JD, Frith, JA, McLeod, JG, Walsh, JC, Garrick, R, Van Der Brink, CM (1980) Transfer factor in treatment of multiple sclerosis. Lancet (8201). 931934.
Bates, D, Fawcett, PRW, Shaw, DA, Weightman, D (1978) Polyunsaturated fatty acids in treatment of acute multiple sclerosis. B. Med. J. ii: 13901391.
Behan, PO, Durward, WF, Melville, ID, McGeorge, AP, Behan, WMH (1976) Transfer factor therapy in multiple sclerosis. Lancet, i: 988990.
Binz, H, Wigzell, H (1975) Shared idiotypic determinants on B and T lymphocytes reactive against the same antigenic determinants. I. Demonstration of similar or identical idiotypes on IgG molecules and T-cell receptors with specificity for the same alloantigens. J. Exp. Med. 142: 197211.
Bolton, C, Borel, JF, Cuzner, ML, Davison, AN, Turner, AM (1982a) Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis. J. Neurol. Sci. 56: 147153.
Bolton, C, Allsopp, G, Cuzner, ML (1982b) The effect of cyclosporin A on the adaptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin. Exp. Immunol. 47: 127132.
Borel, JF, Feurer, C, Gubler, HU, Stahelin, H (1976) Biological effects of cyclosporin A: A new anti-lymphocytic agent. Agents Actions 6: 468475.
Bornstein, MB, Miller, AI, Teitelbaum, D, Arnon, R, Sela, M (1982) Multiple sclerosis: Trial of a synthetic polypeptide. Ann. Neurol. 11:317319.
Britton, S, Palacius, R (1982) Cyclosporin A – usefulness, risks and mechanism of action. Immunological Rev. 65: 522.
Brown, JR, Beebe, GW, Kurtzke, JF, Loewenson, RB, Silberberg, DH, Tourellotte, WW (1979) The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 29: 323.
Campbell, B, Vogel, PJ, Fisher, E, Lorenz, R (1973) Myelin basic protein administration in multiple sclerosis. Arch. Neurol. 29: 1015.
Castaigne, P, Lhermitte, F, Escourolle, R, Hauw, JJ, Gray, F, Lyon-Caen, O (1981) Les Scleroses en plaques asymptomatiques. Rev. Neurol. (Paris). 137: 729739.
Cendrowski, WS (1971) Therapeutic trial of imuran (azathioprine) in multiple sclerosis. Acta Neurol. Scandinav. 47: 254260.
Cendrowski, WS (1973) Combined therapeutic trial in multiple sclerosis. Hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside. Acta Neurol. Belgica 73: 209219.
Cendrowski, W, Cztonkowska, A (1976) Penicillamine in multiple sclerosis. Acta Neurol. Scandinav. 54: 281286.
Cendrowski, W, Cztonkowska, A (1978) Levamisole in multiple sclerosis, with special reference to immunological parameters. A pilot study. Acta Neurol. Scandinav. 57: 354359.
Collins, RC, Espinoza, LR, Plank, CR, Ebers, GC, Rosenberg, RA, Zabriski, JB (1978) A double-blind trial of transfer factor vs. placebo in multiple sclerosis patients. Clin. Exp. Immunol., 33: 111.
Dau, PC, Johnson, KP, Spitler, LE (1976) The effect of levamisole on cellular immunity in multiple sclerosis. Clin. Exp. Immunol. 226: 302309.
Dau, PC, Petajan, JH, Johnson, KP, Panitch, HS, Bornstein, MB (1980) Plasmapheresis in multiple sclerosis: Preliminary findings. Neurology 30: 10238.
Doherty, P, Sampson, E (1982) Murine models of multiple sclerosis, Nature 299: 106107.
Ebers, GC (1982) A study of CSF idiotypes in MS. Scand. J. of Immunol. 16: 151162.
Ebers, GC, Vinuela, FV, Feasby, T, Bass, B (1984) Multifocal CT enhancement in MS. Neurology 34: 341346.
Editorial (1983) Cyclosporin and neoplasia. Lancet, i: 1083.
Fishbeck, KH (1983) Letter: N. Engl. J. Med. 309: 239240.
Fisher, BH, Marks, M, Reich, T (1983) Hyperbaric-oxygen treatment in multiple sclerosis. A randomized placebo-controlled, double-blind study. N. Engl. J. Med. 308: 181–6.
FogT (1965) The long-term treatment of multiple sclerosis with corticoids. Acta Neurol. Scand. 41. (Suppl. 13, Part 2): 473484.
Fog, T, Raun, NS, Pederson, L, Kam-Hansen, S, Mellerup, E (1978) Long-term transfer-factor treatment for multiple sclerosis. Lancet i: 851853.
Frick, E, Angstwurm, H, Blomer, Ret al. (1977) Long-term treatment of multiple sclerosis with azathioprine. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in multiple sclerosis. Ghent, Belgium, European Press, pp. 8898.
Georgi, W (1961) Multiple Sklerose. Pathologisch-anatomische befunde multipler skerose bei Klinisch nicht diagnostizierten Krankheiten. Schqiz Med Wsclv. 91: 605607.
Gilbert, JJ.Sadler, M (1983) Unsuspected multiple sclerosis. Arch Neurol. 40: 533536.
Gonsette, RE, Delmotte, P (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis. J. Neurol. 214: 173181.
Gonsette, RE, Delmotte, P, Demonty, L (1977) Failure of basic protein therapy for multiple sclerosis. J. Neurol. 216: 2731.
Gonsette, RE, Demonty, L, Delmotte, P, de Cock, W, Verhaegen, H, Symoens, J (1982) Modulation of immunity in multiple sclerosis: A doubleblind levamisole-placebo controlled study in 85 patients. J. Neurol. 228: 6572.
Hauser, SL, Dawson, DM, Lehrich, JRet al. (1983) Intensive immunosuppression in progressive multiple sclerosis. N. Eng. J. Med. 308: 173180.
Herndon, RM, Murray, TJ (1983) Proceedings of the International Conference on therapeutic trials in multiple sclerosis. Arch. Neurol. 40: 663710.
Hommes, OR, Lamers, KJB (1977) Immunosuppressive treatment in chronic progressive multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in multiple sclerosis. Ghent, Belgium. European Press, pp. 4864.
Huston, DPet al. (1983) Letter. N. Eng. J. Med. 309: 241.
Jacobs, L, O’Malley, J, Freeman, A, Murawski, J (1982) Intrathecal interferon in multiple sclerosis. Arch. Neurol. 39: 609615.
Jerne, NK (1974) Towards a network theory of the immune system. Ann. Immunol. (Inst. Pasteur). 125C: 373389.
Keith, AB, Arnon, R, Teitelbaum, D, Caspary, EA, Wisniewski, HM (1979) The effect of COP I, a synthetic polypeptide on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. 42: 267274.
Khatri, BO, Harrington, GJ, Schmoll, D, McQuillen, MP (1983) A double-blind randomized controlled study of immunosuppressive drug therapy (IDT) with plasmapheresis (PP) in chronic progressive multiple sclerosis. Neurology. 33 (Suppl. 2): 178179.
Kunkel, HG, Mannik, M, Williams, RC (1963) Individual antigenic specificity of isolated antibodies. Science 140: 12181219.
Kurtzke, JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (DSS). Neurology. 33:14441452.
Lamoureux, G, Cosgrove, J, Duquette, P, Lapierre, Y, Jolicoeur, R, Vanderland, F (1981) A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin. Exp. Immunol. 43: 577584.
Lance, EM, Kriemer, M, Abbosh, J, Jones, VE, Knight, S, Medawar, PB (1975) Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response. Clin. Exp. Immunol. 21: 112.
Lando, Z, Teitelbaum, D, Arnon, R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J. Immunol, 123: 21562160.
Levine, S, Sowinski, R (1977) Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs. Arch. Int. Pharmacodyn. 230: 309318.
Lhermitte, F, Marteau, R.de Saxce, H (1975) Traitement de la sclerose en plaques par le serum antilymphocytaire. In: Immunopathologie due Systeme Nerveux. Schuller, M.E. (editor): Paris, INSERM. 1341:281300.
Lukes, SA, Crooks, LE, Aminoff, MJ, Kaufman, L, Panitch, HS, Mills, C, Norman, D (1983) Nuclear magnetic resonance imaging in multiple sclerosis. Ann. Neurol. 13: 592601.
MacFadyen, DJ, Reeve, CE, Bratty, PJA, Thomas, JW (1973) Failure of antilymphocytic globulin therapy in chronic progressive multiple sclerosis. Neurology. 23: 592598.
McAlpine, D, in McAlpine, D, Lumsden, CE, Acheson, ED (1972) Multiple Sclerosis: A reappraisal. Second Edition, Churchill Livingston, Edinburgh, p. 205.
Mertens, HG, Dommasch, D (1977) Long-term study of immunosuppressive therapy in multiple sclerosis, comparison of periods of the disease before and during treatment. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive Treatment in Multiple Sclerosis. Ghent, Belgium, European Press, pp. 198211.
Mertin, J, Kremer, M, Knight, SCet al. (1982) Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: Final report. Lancet. 2: 351354.
Miller, AE (1983) Letter. N. Eng. J. Med. 309: 240.
Millar, JHD, Vas, CJ, Noronha, MJ, Liversedge, LA, Rawson, MD (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet 2:429–31.
Myers, LW, Ellison, GW, Levy, J, Holevoet, MI, Ma, BI, Tourtellotte, WW (1977). Evaluation of levamisole as a treatment for multiple sclerosis. Neurology 27: 363.
Noseworthy, JH, Paty, DW, Wonnacott, T, Ebers, GC (1983) The markers of prognosis in multiple sclerosis. Ann. Neurol 14: 114.
Noseworthy, JH, Buonanno, FS, Kistler, JP, Rosen, B, New, PFJ, Brady, TJ (1984) True three-dimensional nuclear magnetic resonance neuroimaging in multiple sclerosis. (Submitted, Neurology).
Nussenblatt, RB, Rook, AH, Wacker, WB, Palestine, AG, Scher, I, Gery, I (1983) Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. (8344). 235238.
Oger, J, Deugnier, Y, Hinault, P, Sabouraud, O (1977) Experience of long term immunosuppressive therapy in multiple sclerosis. In: Delmotte, P., Hommes, O.R., Gonsette, R. (Editors): Immunosuppressive treatment in Multiple Sclerosis. Ghent, Belgium. European Press. pp. 100113.
Oudin, J, Michel, M (1963) Une nouvelle forme d’allotypie des globulins Ŏ du serum de lapin apparement liée a la fonction et a la spécificité auticorps. C.R. Acad. Sci. 257: 805808.
Paterson, PY, Hanson, MA (1969) Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J. Immunol. 103: 13111316.
Paty, DW, Cousin, HK, Read, S, Adlakha, K (1978) Linoleic acid in multiple sclerosis: Failure to show any therapeutic benefit. Acta Neurol. Scandinav. 58: 5358.
Patzgold, U, Haller, P, Haas, J, Pocklington, P, Dreicher, H (1979) Therapie der multiplen sklerose mit levamisole und azathioprine. Nervenarzt. 49: 285294.
Patzgold, U, Hecker, H, Pocklington, P (1982) Azathioprine in treatment of multiple sclerosis. J. Neurol. Sci. 54: 377394.
Penn, I (1982) Malignancies following the use of cyclosporin A in man. Cancer Surveys. 1:621624.
Penn, I (1982) Malignancies following the use of cyclosporin A in man. Cancer Surveys. 1: 621624.
Phadke, JG, Best, PV (1983) Atypical and clinically silent multiple sclerosis. A report of 12 cases discovered unexpectedly at necropsy. J. Neurol. Neurosurg. Psychiat. 46: 414421.
Polak, L, Turk, JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature (Lond.). 249: 654.
Poser, CM, Paty, DW, Scheinberg, Let al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocals. Ann. Neurol. 13:227231.
Ring, J, Lob, G, Angstwurm, H, Brass, B, Backmund, H, Seiffert, J, Coulin, K, Frick, E, Mertin, J, Brandel, W (1974) Intensive immunosuppression in the treatment of multiple sclerosis. Lancet (7889). 10931096.
Rodkey, LS (1980) Autoregulation of immune responses via idiotype network interactions, Microbiol. Rev. 44: 631659.
Romine, JS, Salk, J (1983) A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis. In: Hallpike, JF, Adams, CWM, Tourtellotte, WW (Editors): Multiple Sclerosis. Williams and Wilkins, Baltimore, pp. 621630.
Rose, AS, Kuzma, JW, Kurtzke, JFet al. (1970) Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs placebo. Neurology 20 (Suppl.) 159.
Rosen, J A (1979) Prolonged azathioprine treatment of nonremitting multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 42: 338344.
Schuller, E, Govaerts, A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur. Neurol. 22:205212.
Schumacher, GA, Beebe, G, Kibler, RFet al. (1965) Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. NY Acad. Sci. 122: 552568.
Seland, TP, McPherson, TA, Grace, M, Lamoureux, G, Blain, JG (1974) Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. Neurology 24: 3440.
Silberberg, D, Lisak, R, Zweiman, B (1973) Multiple sclerosis unaffected by azathioprine in pilot study. Arch. Neurol. 28: 210212.
Steinman, L, Rosenbaum, JT, Sriram, S, McDevitt, HO (1981) In vivo effects of antibodies to immune response gene products; Prevention of experimental allergic encephalitis. Proc. Natl. Acad. Sci. U.S.A. 78:71117114.
Stiller, CR, Laupacis, A, Dupre, J, Jennar, MR, Keown, PA, Rodger, W, Wolfe, BMJ (1983) Cyclosporin for treatment of early type 1 diabetes: preliminary results. N. Eng. J. Med. 308: 12261227.
Swinburn, WR, Liversedge, LA (1973) Long-term treatment of multiple sclerosis with azathioprine. J. Neurol. Neurosurg. Psychiat. 36:124126.
Teitelbaum, D, Webb, C, Bree, Met al. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3: 256262.
Theys, P, Gosseye – Lissoir, F, Ketelaer, P, Carton, H (1981) Short-term intensive cyclophosphamide treatment in Multiple Sclerosis. J. Neurol. 225: 119133.
Tindall, RSA, Walker, JE, Ehle, AL, Near, L, Rollins, J, Becker, D (1982) Plasmaphresis in multiple sclerosis. Prospective trial of pheresis and immunosuppression verses immunosuppression alone. Neurology. 32: 739743.
Weiner, HL, Dawson, DM (1980) Plasmapheresis in multiple sclerosis: Preliminary study. Neurology (Minneap.). 30: 102933.
Whitaker, JN, Lisak, RP, Bashir, RM, Fitch, OH, Seyer, JM, Krance, R, Lawrence, JA, Ch’ien, LT, O’Sullivan, PO (1978) Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann. Neurol. 7: 5864.
White, DJG (Editor) Cyclosporin A (1982) New York, Elsevier Press.
Young, IR, Hall, AS.Pallis, CA, Bydder, GM, Legg, NJ, Steiner, RE (1981) Nuclear Magnetic resonance imaging of the brain in multiple sclerosis. Lancet (8255) 10631066.

Editorial Review: Therapeutic Trials in Multiple Sclerosis

  • J.H. Noseworthy (a1), T.P. Seland (a1) and G.C. Ebers (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.